Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | 2C20H25N3O4.2C4H6O5.H2O |
| Molecular Weight | 1029.0506 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.OC(CC(O)=O)C(O)=O.OC(CC(O)=O)C(O)=O.COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N3C[C@@H](C)C[C@H](N)C3)C4CC4.COC5=C6N(C=C(C(O)=O)C(=O)C6=CC=C5N7C[C@@H](C)C[C@H](N)C7)C8CC8
InChI
InChIKey=XNVZOGKOFKLWFQ-ABLBMNRKSA-N
InChI=1S/2C20H25N3O4.2C4H6O5.H2O/c2*1-11-7-12(21)9-22(8-11)16-6-5-14-17(19(16)27-2)23(13-3-4-13)10-15(18(14)24)20(25)26;2*5-2(4(8)9)1-3(6)7;/h2*5-6,10-13H,3-4,7-9,21H2,1-2H3,(H,25,26);2*2,5H,1H2,(H,6,7)(H,8,9);1H2/t2*11-,12-;;;/m00.../s1
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C20H25N3O4 |
| Molecular Weight | 371.4302 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C4H6O5 |
| Molecular Weight | 134.0874 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Nemonoxacin is a non-fluorinated quinolone antibiotic in clinical development in an oral and intravenous formulation. It exhibits potent antibacterial activities against Gram-positive, Gram-negative, and atypical pathogens, especially methicillin-resistant Staphylococcus aureus. The molecule inhibits bacterial DNA synthesis by forming a ternary complex with a DNA molecule and gyrase and topoisomerase IV enzymes, thus blocking bacterial DNA supercoiling. Nemonoxacin is developed by TaiGen Biotechnology Company and has reached worldwide approval in 2014 and is marketed under the name Taigexyn®.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| New antibiotics for antibiotic-resistant bacteria. | 2009 May 28 |
|
| Gateways to clinical trials. | 2010 Jun |
|
| In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. | 2010 Nov |
|
| In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007. | 2010 Nov |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:08:14 GMT 2023
by
admin
on
Sat Dec 16 03:08:14 GMT 2023
|
| Record UNII |
Y97F3051FH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID10241765
Created by
admin on Sat Dec 16 03:08:14 GMT 2023 , Edited by admin on Sat Dec 16 03:08:14 GMT 2023
|
PRIMARY | |||
|
951313-26-1
Created by
admin on Sat Dec 16 03:08:14 GMT 2023 , Edited by admin on Sat Dec 16 03:08:14 GMT 2023
|
PRIMARY | |||
|
Y97F3051FH
Created by
admin on Sat Dec 16 03:08:14 GMT 2023 , Edited by admin on Sat Dec 16 03:08:14 GMT 2023
|
PRIMARY | |||
|
71587894
Created by
admin on Sat Dec 16 03:08:14 GMT 2023 , Edited by admin on Sat Dec 16 03:08:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |